Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts

Ammaar Abidi, Chaela S. Presley, Mustafa Dabbous, David Tipton, Suni M. Mustafa, Bob Moore

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives Approximately 65 million adults in the US have periodontitis, causing tooth loss and decreased quality of life. Cannabinoids modulate immune responses, and endocannabinoids are prevalent during oral cavity inflammation. Targets for intervention in periodontal inflammation are cannabinoid type 1 and 2 receptors (CB1R, CB2R), particularly CB2R because its levels increase during inflammation. We previously demonstrated that SMM-189 (CB2R inverse agonist) decreased pro-inflammatory cytokine production in primary microglial cells. The hypothesis of this study was that cannabinoids anandamide (AEA), HU-308 (CB2R selective agonist), and SMM-189 decrease pro-inflammatory IL-6 and MCP-1 production by primary human periodontal ligament fibroblasts (hPDLFs) stimulated with P. gingivalis LPS, TNF-α, or IL-1β. Design Cytotoxic effects of cannabinoid compounds (10−4–10−6.5 M), LPS (1–1000 ng/ml), TNFα (10 ng/ml) and IL-1β (1 ng/ml) were assessed by measuring effects on cellular dehydrogenase activity. IL-6 and MCP-1 production were measured using Mesoscale Discovery (MSD) Human Pro-Inflammatory IL-6 and MSD Human Chemokine MCP-1 kits and analyzed using MSD Sector 2400 machine. Results EC50 values for AEA, SMM-189, and HU-308 were 16 μM, 13 μM, and 7.3 μM respectively. LPS (1 μg/ml), TNF-α (10 ng/ml), and IL-1β (1 ng/ml) increased IL-6 and MCP-1 production, which were inhibited by AEA, SMM-189, and HU-308. AEA alone significantly increased IL-6, but not MCP-1 levels, but the other cannabinoids alone had no effect. Conclusion The effective inhibition of LPS, TNF-α, IL-1β stimulated IL-6 and MCP-1 production by CB2R ligands in hPDLFs suggests that targeting the endocannabinoid system may lead to development of novel drugs for periodontal therapy, aiding strategies to improve oral health.

Original languageEnglish (US)
Pages (from-to)79-85
Number of pages7
JournalArchives of Oral Biology
Volume87
DOIs
StatePublished - Mar 1 2018

Fingerprint

Cannabinoid Receptors
Cannabinoids
Interleukin-6
Anti-Inflammatory Agents
Fibroblasts
Ligands
Interleukin-1
Endocannabinoids
Periodontal Ligament
Inflammation
Tooth Loss
Periodontitis
Oral Health
Chemokines
Mouth
Oxidoreductases
Quality of Life
Cytokines
Drug Therapy
SMM-189

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Dentistry(all)
  • Cell Biology

Cite this

Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts. / Abidi, Ammaar; Presley, Chaela S.; Dabbous, Mustafa; Tipton, David; Mustafa, Suni M.; Moore, Bob.

In: Archives of Oral Biology, Vol. 87, 01.03.2018, p. 79-85.

Research output: Contribution to journalArticle

@article{33c264b786ec4727965ef9a9bb8b8789,
title = "Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts",
abstract = "Objectives Approximately 65 million adults in the US have periodontitis, causing tooth loss and decreased quality of life. Cannabinoids modulate immune responses, and endocannabinoids are prevalent during oral cavity inflammation. Targets for intervention in periodontal inflammation are cannabinoid type 1 and 2 receptors (CB1R, CB2R), particularly CB2R because its levels increase during inflammation. We previously demonstrated that SMM-189 (CB2R inverse agonist) decreased pro-inflammatory cytokine production in primary microglial cells. The hypothesis of this study was that cannabinoids anandamide (AEA), HU-308 (CB2R selective agonist), and SMM-189 decrease pro-inflammatory IL-6 and MCP-1 production by primary human periodontal ligament fibroblasts (hPDLFs) stimulated with P. gingivalis LPS, TNF-α, or IL-1β. Design Cytotoxic effects of cannabinoid compounds (10−4–10−6.5 M), LPS (1–1000 ng/ml), TNFα (10 ng/ml) and IL-1β (1 ng/ml) were assessed by measuring effects on cellular dehydrogenase activity. IL-6 and MCP-1 production were measured using Mesoscale Discovery (MSD) Human Pro-Inflammatory IL-6 and MSD Human Chemokine MCP-1 kits and analyzed using MSD Sector 2400 machine. Results EC50 values for AEA, SMM-189, and HU-308 were 16 μM, 13 μM, and 7.3 μM respectively. LPS (1 μg/ml), TNF-α (10 ng/ml), and IL-1β (1 ng/ml) increased IL-6 and MCP-1 production, which were inhibited by AEA, SMM-189, and HU-308. AEA alone significantly increased IL-6, but not MCP-1 levels, but the other cannabinoids alone had no effect. Conclusion The effective inhibition of LPS, TNF-α, IL-1β stimulated IL-6 and MCP-1 production by CB2R ligands in hPDLFs suggests that targeting the endocannabinoid system may lead to development of novel drugs for periodontal therapy, aiding strategies to improve oral health.",
author = "Ammaar Abidi and Presley, {Chaela S.} and Mustafa Dabbous and David Tipton and Mustafa, {Suni M.} and Bob Moore",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.archoralbio.2017.12.005",
language = "English (US)",
volume = "87",
pages = "79--85",
journal = "Archives of Oral Biology",
issn = "0003-9969",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts

AU - Abidi, Ammaar

AU - Presley, Chaela S.

AU - Dabbous, Mustafa

AU - Tipton, David

AU - Mustafa, Suni M.

AU - Moore, Bob

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objectives Approximately 65 million adults in the US have periodontitis, causing tooth loss and decreased quality of life. Cannabinoids modulate immune responses, and endocannabinoids are prevalent during oral cavity inflammation. Targets for intervention in periodontal inflammation are cannabinoid type 1 and 2 receptors (CB1R, CB2R), particularly CB2R because its levels increase during inflammation. We previously demonstrated that SMM-189 (CB2R inverse agonist) decreased pro-inflammatory cytokine production in primary microglial cells. The hypothesis of this study was that cannabinoids anandamide (AEA), HU-308 (CB2R selective agonist), and SMM-189 decrease pro-inflammatory IL-6 and MCP-1 production by primary human periodontal ligament fibroblasts (hPDLFs) stimulated with P. gingivalis LPS, TNF-α, or IL-1β. Design Cytotoxic effects of cannabinoid compounds (10−4–10−6.5 M), LPS (1–1000 ng/ml), TNFα (10 ng/ml) and IL-1β (1 ng/ml) were assessed by measuring effects on cellular dehydrogenase activity. IL-6 and MCP-1 production were measured using Mesoscale Discovery (MSD) Human Pro-Inflammatory IL-6 and MSD Human Chemokine MCP-1 kits and analyzed using MSD Sector 2400 machine. Results EC50 values for AEA, SMM-189, and HU-308 were 16 μM, 13 μM, and 7.3 μM respectively. LPS (1 μg/ml), TNF-α (10 ng/ml), and IL-1β (1 ng/ml) increased IL-6 and MCP-1 production, which were inhibited by AEA, SMM-189, and HU-308. AEA alone significantly increased IL-6, but not MCP-1 levels, but the other cannabinoids alone had no effect. Conclusion The effective inhibition of LPS, TNF-α, IL-1β stimulated IL-6 and MCP-1 production by CB2R ligands in hPDLFs suggests that targeting the endocannabinoid system may lead to development of novel drugs for periodontal therapy, aiding strategies to improve oral health.

AB - Objectives Approximately 65 million adults in the US have periodontitis, causing tooth loss and decreased quality of life. Cannabinoids modulate immune responses, and endocannabinoids are prevalent during oral cavity inflammation. Targets for intervention in periodontal inflammation are cannabinoid type 1 and 2 receptors (CB1R, CB2R), particularly CB2R because its levels increase during inflammation. We previously demonstrated that SMM-189 (CB2R inverse agonist) decreased pro-inflammatory cytokine production in primary microglial cells. The hypothesis of this study was that cannabinoids anandamide (AEA), HU-308 (CB2R selective agonist), and SMM-189 decrease pro-inflammatory IL-6 and MCP-1 production by primary human periodontal ligament fibroblasts (hPDLFs) stimulated with P. gingivalis LPS, TNF-α, or IL-1β. Design Cytotoxic effects of cannabinoid compounds (10−4–10−6.5 M), LPS (1–1000 ng/ml), TNFα (10 ng/ml) and IL-1β (1 ng/ml) were assessed by measuring effects on cellular dehydrogenase activity. IL-6 and MCP-1 production were measured using Mesoscale Discovery (MSD) Human Pro-Inflammatory IL-6 and MSD Human Chemokine MCP-1 kits and analyzed using MSD Sector 2400 machine. Results EC50 values for AEA, SMM-189, and HU-308 were 16 μM, 13 μM, and 7.3 μM respectively. LPS (1 μg/ml), TNF-α (10 ng/ml), and IL-1β (1 ng/ml) increased IL-6 and MCP-1 production, which were inhibited by AEA, SMM-189, and HU-308. AEA alone significantly increased IL-6, but not MCP-1 levels, but the other cannabinoids alone had no effect. Conclusion The effective inhibition of LPS, TNF-α, IL-1β stimulated IL-6 and MCP-1 production by CB2R ligands in hPDLFs suggests that targeting the endocannabinoid system may lead to development of novel drugs for periodontal therapy, aiding strategies to improve oral health.

UR - http://www.scopus.com/inward/record.url?scp=85038953206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038953206&partnerID=8YFLogxK

U2 - 10.1016/j.archoralbio.2017.12.005

DO - 10.1016/j.archoralbio.2017.12.005

M3 - Article

VL - 87

SP - 79

EP - 85

JO - Archives of Oral Biology

JF - Archives of Oral Biology

SN - 0003-9969

ER -